Efficacy and Safety of Domestic Leuprorelin in Girls with Idiopathic Central Precocious Puberty: A Multicenter, Randomized, Parallel, Controlled Trial

Wen-Jing Li¹, Chun-Xiu Gong¹, Mei-Jie Guo¹, Jie Xing¹, Tang Li¹, Wen-Hui Song¹, Xiao-Ping Luo¹, Di Wu¹, Jian-Ping Liang¹, Bing-Yan Cao¹, Yi Gu¹, Chang Su¹, Xue-Jun Liang¹, Min Liu¹, Rui Wang¹, Feng-Ting Li¹

¹Department of Endocrine and Genetic Metabolic, Beijing Children’s Hospital, Capital Medical University, Beijing 100045, China

Background: In central precocious puberty (CPP), the pulse secretion and release of gonadotropin-releasing hormone (GnRH) are increased due to early activation of the hypothalamic-pituitary-gonadal axis, resulting in developmental abnormalities with gonadal development and appearance of secondary sexual characteristics. The CPP without organic disease is known as idiopathic CPP (ICPP). The objective of the study was to evaluate the clinical efficacy and safety of domestic leuprorelin (GnRH analog) in girls with ICPP.

Methods: A total of 236 girls with ICPP diagnosed from April 2012 to January 2014 were selected and were randomized into two groups. One hundred fifty-seven girls in the test group were treated with domestic leuprorelin acetate, 79 girls in the control group were treated with imported leuprorelin acetate. They all were treated and observed for 6 months. After 6-month treatment, the percentage of children with peak luteinizing hormone (LH) ≤3.3 U/L, the percentage of children with peak LH/peak follicle stimulating hormone (FSH) ratio <0.6, the improvements of secondary sexual characteristics, gonadal development and sex hormone levels, the change of growth rate of bone age (BA) and growth velocity, and drug adverse effects between two groups were compared.

Results: After the treatment, the percentage of children with a suppressed LH response to GnRH, defined as a peak LH ≤3.3 U/L, at 6 months in test and control groups were 96.80% and 96.20%, respectively, and the percentage of children with peak LH/FSH ratio ≤0.6 at 6 months in test and control groups were 93.60% and 93.70%, respectively. The sizes of breast, uterus and ovary of children and the levels of estradiol (E₂) were significantly reduced, and the growth rate of BA was also reduced. All the differences between pre- and post-treatment in each group were statistically significant (P < 0.05), but the differences of the parameters between two groups were not significant (P > 0.05).

Conclusions: Domestic leuprorelin is effective and safe in the treatment of Chinese girls with ICPP. Its effectiveness and safety are comparable with imported leuprorelin.

Key words: Central Precocious Puberty; Gonadotropin-releasing Hormone Analog; Idiopathic Central Precocious Puberty; Leuprorelin
National Medical Center showed that within 8 years between 1995 and 2003, the age of sexual maturity in girls was 1 year advanced. The incidence of precocious puberty in children in Chinese coastal areas is 0.38%, of them the incidence of precocious puberty in girls is higher (0.67%). The incidence of precocious puberty in Shanghai is 1% and the incidence of precocious puberty in Juizhang city is 0.68%, of them it is up to 1.25% in girls, and 0.11% in boys; the incidence is up to 0.74% in Zhengzhou.

The objectives of CPP therapies are to inhibit premature or excessive sexual development and improve impaired adult height due to advance bone age (BA), to prevent psychosocial problems associated with prematurity and early menarche. Currently, the preferred drug in the world for treatment of CPP is GnRH analog (GnRHa), which is a high-active derivative of GnRH.

Gonadotropin-releasing hormone analog sustained-release agent key products are agent key products in the treatment of CPP, including leuprorelin acetate and triptorelin acetate. Most agents of leuprorelin in China are imported branded products. In 2009, a domestic agent of leuprorelin acetate was marketed, and was studied for the treatment of endometriosis in adults. Its safety and efficacy had no difference compared with an imported agent of leuprorelin acetate. Currently, there is no large multi-center clinical study data on the comparison of domestic and imported leuprorelin acetate. In order to demonstrate the efficacy and safety of domestic leuprolide in the treatment of CPP, and based on specific patient population—children, we designed this study with caution.

Methods

Study population

This trial included 236 girls with ICPP who were diagnosed in Beijing Children’s Hospital, Tongji Hospital, Harbin Children’s Hospital, Affiliated Hospital of Qingdao University, Shanxi Children’s Hospital, and Second Hospital of Jilin University between April 2012 and January 2014. This clinical trial has been approved by the Ethics Committee of Beijing Children’s Hospital, and the informed consents were obtained from all participated children and parents.

All the cases met the following inclusion and exclusion criteria. Inclusion criteria included: (1) Early appearance of secondary sexual characteristics: Girls ≤8 years; (2) Enlarged gonad: Under the B-ultrasound, the ovary volume >1 ml, more than 4 follicles with diameter ≥4 mm in unilateral ovary were observed; (3) Serum gonadotropins (including that luteinizing hormone [LH] and follicle stimulating hormone [FSH] level rose to the pubertal level): First, routine screening of baseline LH, if the baseline serum LH >3.3 U/L, the onset of gonadal axis can be determined, the condition was met; if baseline serum LH <3.3 U/L, the GnRH stimulation test was conducted; secondly, GnRH stimulation test: The stimulated peak value in the test can be used as diagnostic basis, the peak value referred to the maximum value of LH and FSH at each time-point in the stimulation test, which occurred at 60–120 min; for detection at 60 min, with immune chemiluminescence assay, when peak LH >3.3 U/L and peak LH/peak FSH >0.6 in the GnRHa stimulation test, CPP can be diagnosed; (4) Growth velocity (GV) spurted; (5) BA exceeded: BA increased by more than 1-year compared with the actual age.

Exclusion criteria included: (1) Congenital hypothyroidism; (2) Peripheral precocious puberty: Germ cell tumors and various types of gonadal tumors; (3) Organic diseases including congenital adrenal hyperplasia, adrenal tumors, various intracranial tumors; (4) Precocious puberty resulted by central nervous system diseases; (5) Exogenous precocious puberty, such as medicines, hormones, or pollute; (6) Patient who had used corticosteroid within 3 months before enrollment; (7) ICPP patient who had used GnRHa.

Case drop-out and elimination criteria: Those who did not meet the inclusion criteria or had no follow-up information record were eliminated. The eliminated cases were not included in the efficacy analysis. The drop-out case was defined as those who did not complete the follow-up prescribed in the protocol, included: (1) Patients who requested to withdraw from the study; (2) Posed potential risks to patients based on the judgment by investigator; (3) Serious adverse events; and (4) Patients who lost to follow-up. The specific reasons should be recorded for drop-out cases, which should be included in the full analysis set (FAS) and the safety analysis set.

Sample size estimation

There were two treatment groups in this study. The percentages of patients with “baseline serum LH <upper limit of normal (0.1 U/L)” or “peak LH in response to the drug <3.3 U/L (or peak LH/peak FSH ratio <0.6)” at 6 months after the treatment between two groups were compared. It was expected that the mean percentage was 90%. Noninferiority test was applied, \( \alpha = 0.025, \beta = 0.2 \) (power = 80%), \( \delta = 12.5\% \), the ratio of the test group to the control was 2:1, the estimated results: 136 cases in the test group and 68 cases in the control group, considering the factor of drop-out, it increased to 160 cases in the test group, 80 cases in the control group, a total of 240 cases.

Methods

Cases in the study were randomized into the test group and the control group. Girls in the test group were treated with domestic leuprorelin acetate microspheres for injection (3.75 mg/vial, produced by Shanghai Livzon Pharmacy Co., Ltd., trade name: Beiyi). Girls in the control group were treated with leuprorelin acetate microspheres for injection (3.75 mg/vial, produced by Takeda Pharmaceutical Co., Ltd., Japan; trade name: Enantone), the dose in both groups was 3.75 mg, subcutaneous injection every 4 weeks for 6 months.

Central randomization was used for grouping in the study. Dynamic randomization system provided by statistical professionals from the Clinical Research Center, Shanghai University of Traditional Chinese Medicine was used for
the centralized randomization procedure. After screening every eligible patient, investigators participated in the study in each site logged in the system, entered the screening information, obtained a random number (e.g., drug number), provided corresponding investigational drug based on the random number.

The investigational medicinal product in this study is a marketed product. The product could not be designed as a double-blind study because there is the logo of the company on the package. Consequently, this trial was conducted with the investigator-isolated blinded method, in which patients were enrolled sequentially and were provided with the product. Staff who provided and injected the product received the drug according to the random numbers and did not exchange the allocating information with the observing investigators. The product was blinded to the laboratory technicians who measured blood hormones, and the doctors who conducted the genital ultrasound.

**Data collection**
The improvements of secondary sexual characteristics (breasts, pubic hair, menstruation, armpit hair), gonadal development (pelvic B-ultrasound), and serum sex hormone level (E2) at 0, 3, 6 month(s) after the treatment were observed.

The changes of growth rate of BA and GV at 0, 6 month(s) after the treatment were recorded, these were calculated with GV, standard deviation score of height (HtSDS). The adverse effects were monitored and recorded. The changes of renal function, blood lipids, bone metabolism, urine routine test, body mass index, injection site pain, rash or abscess, vaginal bleeding, and polycystic ovary at 0, 3, 6 month(s) after the treatment were recorded. These were estimated for causality based on the standards of China Food and Drug Administration.

Height and weight (measured by a specified person with the same tools in each center) were measured monthly for each patient during the treatment. Three measurements were conducted, and the results were averaged; BA was determined using Greulich-Pyle method; ellipsoid volume formula was conducted, and the results were averaged; BA was determined on the package. Consequently, this trial was conducted in a double-blind study because there is the logo of the company marketed product. The product could not be designed as a double-blind study. Informed consent

**Clinical efficacy evaluation**
The primary efficacy endpoints: The percentage of patients met the LH criterion at 6 months after the treatment, e.g., the percentage of patients with “baseline serum LH < upper limit of normal” or “peak LH in response to the drug < 3.3 U/L or peak LH/peak FSH ratio < 0.6.”

The secondary efficacy endpoints: The improvement of secondary sexual characteristics (breasts, pubic hair, menstruation, armpit hair), gonadal development (pelvic B-ultrasound), and serum sex hormone level (E2) at 0, 3, 6 month(s) after the treatment were compared. The changes of growth rate of BA and GV at 0, 6 month(s) after the treatment were compared, these were calculated with GV, HtSDS.

**Statistical analysis**
Statistics Analysis System (SAS) 9.2 software (USA) was used for analyses. Three analytic data sets (FAS, per protocol set [PPS], safety set [SS]) were determined. Demographic data were shown as mean ± SD. Two-sided 95% confidence interval (CI) of the percentage difference for patients whose primary efficacy endpoint LH met its criterion was tested by noninferiority test based on 12.5% of noninferiority criteria (FAS, PPS). For all secondary efficacy endpoints, two-sided test was used in the general statistical test; independent sample t-test was used in the comparisons between two groups; paired t-test was used in the comparisons between pre- and post-treatment. A P ≤ 0.05 was considered as statistically significance for a tested difference (FAS). The incidences of adverse events and adverse reactions were calculated in the safety evaluation (SS).

**Results**

**Case distribution and baseline equilibrium**
Two hundred and forty cases were included in the study. One hundred sixty cases were included in the test group (Beiyi), 3 of them were eliminated. All the PPS, FAS, and SS sets had 157 cases; 80 cases were included in the control group (Enantone), 1 of them was eliminated. All the PPS, FAS, and SS sets had 79 cases [Figure 1].

All the 236 subjects in this trial were girls with ICPP, and the demographic and clinical characteristics were shown in Table 1. In the test group, the initial age was 6.42 ± 1.01 years, the initial BA was 9.22 ± 1.43 years; according to Tanner’s staging for puberty development, there were 71 cases of breast Stage II, 70 cases of breast Stage III, 5 cases of breast Stage IV; 17 cases of pubic hair Stage II, 3 cases of pubic hair Stage III, the remaining girls were pubic hair Stage I; menarche appeared in 10 cases; armpit

**Figure 1:** The treatment flow chart of the patient.
The primary efficacy endpoint: The percentage of patients met the peak luteinizing hormone criterion

The percentage of patients with peak LH in response to the drug <3.30 U/L was 96.80% and 96.20% at 6 months after the treatment in patients of the test group and the control group, respectively. There was no significant difference between two groups (P > 0.05) [Figure 2]; the percentage of patients with peak LH/peak FSH <0.6 was 93.60% and 93.70% at 6 months after the treatment in patients of two groups, respectively, there was no significant difference between two groups (P > 0.05) [Figure 2].

For FAS analysis, the percentages of patients met the peak LH criterion in both test (Beiyi) and control groups (Enantone) were 100%, the lower limit of 95% CI for the rate of difference between two groups was 0. The test group was noninferior compared with the control group based on the noninferiority criteria of 12.5%.

Changes in secondary sexual characteristics

Patients in the test and the control groups developed manifestations that the mammary gland mass became softer and smaller, and the breast shrank. In the test group, 20 cases developed pubic hair growth before the treatment; which remained unchanged in 14 cases after the treatment, decreased slightly in 5 cases, progressed from Stage I to Stage II in 1 case. In the control group, 5 cases developed pubic hair growth before the treatment; which remained unchanged in 3 cases after the treatment, decreased slightly in 2 cases. Before the treatment, 10 cases developed menarche in the test group, and 4 cases developed menarche in the control group, all of which were disappeared at 1 month after the treatment. Before the treatment, 3 cases developed armpit hair growth in the test group, and 2 cases developed armpit hair growth in the control group, which decreased after the treatment in 2 cases in both groups, and 1 case remained unchanged in the test group.

Pelvic B-ultrasound

The uterus volume of patients before therapy in test and control groups was higher than the prepubertal level (3 cm³), and significantly decreased at 3 months after the treatment. The differences were significant compared with the pretreatment levels in each group (all P < 0.05). The uterus volume of patients before therapy in test and control groups decreased to the prepubertal level after 6 months treatment, the difference of those between 6 months and

Table 1: The demographic and clinical characteristics of ICPP girls

| Items                                      | Test group (n = 157) | Control group (n = 79) | t     | P    |
|--------------------------------------------|----------------------|------------------------|-------|------|
| Age (mean ± SD, years)                     | 6.42 ± 1.01          | 6.47 ± 0.75            | 0.411 | 0.682|
| Weight (mean ± SD, kg)                     | 27.50 ± 5.40         | 27.3 ± 5.00            | 0.277 | 0.782|
| Height (mean ± SD, cm)                     | 130.00 ± 8.00        | 129.00 ± 5.00          | 1.182 | 0.238|
| GV at 1 year before enrollment (mean ± SD, cm/year) | 7.43 ± 1.36          | 7.70 ± 1.62            | 1.330 | 0.185|
| Tanner’s staging of breast development (mean ± SD, stage) | 2.44 ± 0.67          | 2.32 ± 0.59            | 1.380 | 0.169|
| Tanner’s staging of pubic hair development (mean ± SD, stage) | 1.15 ± 0.41          | 1.08 ± 0.31            | 1.480 | 0.140|
| Tanner’s staging of armpit hair development (mean ± SD, stage) | 1.02 ± 0.14          | 1.03 ± 0.16            | 0.311 | 0.756|
| Uterus volume (mean ± SD, cm³)             | 3.40 ± 2.90          | 3.13 ± 2.27            | 0.782 | 0.435|
| Left ovary (ml)                            | 2.21                 | 2.15                   | 0.183 | 0.669|
| Number of follicles with diameter ≥4 mm in the left ovary (n) | 4.80                 | 4.66                   | 0.141 | 0.707|
| Right ovary (ml)                           | 1.96                 | 1.93                   | 0.340 | 0.560|
| Number of follicles with diameter ≥4 mm in the right ovary (n) | 4.21                 | 3.78                   | 3.863 | 0.049|
| BA (mean ± SD, years)                      | 9.22 ± 1.43          | 9.11 ± 1.18            | 0.585 | 0.599|
| BA-CA (mean ± SD, years)                   | 2.19 ± 1.07          | 2.18 ± 1.00            | 0.114 | 0.909|
| LH (mean ± SD, U/L)                        | 1.83 ± 2.71          | 2.14 ± 3.14            | 0.773 | 0.440|
| Follicle stimulating hormone (mean ± SD, U/L) | 4.43 ± 2.91          | 4.77 ± 3.42            | 0.794 | 0.428|
| Estradiol (mean ± SD, ×10⁶ mg/L)           | 37.1 ± 14.7          | 36.0 ± 17.3            | 0.519 | 0.604|
| Testosterone (mean ± SD, ×10⁹ mg/L)        | 4.34 ± 6.50          | 4.57 ± 5.78            | 0.265 | 0.791|
| Baseline LH (mean ± SD, U/L)               | 2.37 ± 3.80          | 2.16 ± 2.99            | 0.444 | 0.657|
| Peak LH (mean ± SD, U/L)                   | 16.60 ± 7.50         | 16.40 ± 6.60           | 0.237 | 0.813|

SD: Standard deviation; ICPP: Idiopathic central precocious puberty; LH: Luteinizing hormone; BA: Bone age; GV: Growth velocity; CA: Chronology age.
3 months after the treatment was significant ($P < 0.05$).
The differences of the uterus volume before treatment and 3 months after the treatment between two groups were not significant (all $P > 0.05$). The difference at 6 months after the treatment between two groups was significant ($P < 0.05$) [Table 2]. Bilateral ovaries volume before therapy increased significantly compared with the prepubertal level (1 ml) in patients of test and control groups. It was decreasing with the course of treatment and reached the prepubertal level at 6 months after the treatment. The difference at 6 months after the treatment of two groups was significant (all $P < 0.05$) compared with pretreatment. There was no significant difference between two groups before the treatment and after the treatment ($P > 0.05$) [Table 2]. Follicles with diameter $\geq$4 mm were observed in unilateral ovary in all patients of both groups; all of these follicles decreased or disappeared after the treatment.

**Changes in hormone levels**

The serum E$_2$ level before the treatment was significantly higher than the prepubertal level ($<2 \times 10^{-3}$ mg/L) in patients of test and control groups, and significantly decreased at 3 months and 6 months after the treatment, the differences between pre- and post-treatment in each group were significant ($P < 0.05$). There was no significant difference before and after the treatment between two groups ($P > 0.05$) [Table 2].

The peak LH after GnRH stimulation test at 6 months after treatment in all patients of test and control groups, and significantly decreased or disappeared after the treatment.

**Bone age and growth velocity**

The growth rate of BA was decreased after the treatment in all patients of test and control groups. Before the treatment, the CA was $6.42 \pm 0.71$ years and $6.47 \pm 0.75$ years, respectively; BA was $9.22 \pm 1.43$ years and $9.11 \pm 1.18$ years, respectively; the difference of BA-CA was $2.19 \pm 1.07$ years and $2.18 \pm 1.00$ years, respectively. At 6 months after the treatment, BA was $9.24 \pm 1.36$ years and $9.16 \pm 1.18$ years, respectively, the difference of BA-CA was $0.72 \pm 1.03$ years and $0.73 \pm 0.99$ years, respectively; the growth rate of BA was significantly lower than that of CA; all the differences of these were not significant between two groups ($P > 0.05$) [Table 2].

The GV was decreasing with the course of treatment after the treatment in patients of test and control groups. After 6 months of treatment, the HtSDSCA of patients in two groups was decreased from $0.71 \pm 0.29$, $0.69 \pm 0.29$ to $0.70 \pm 0.30$, $0.69 \pm 0.29$, respectively; and the HtSDSBA was increased from $−0.47 \pm 0.48$ and $−0.48 \pm 0.40$ to $−0.24 \pm 0.55$ and $−0.21 \pm 0.57$, respectively. All the differences between them before the treatment and 6 months after the treatment were significant ($P < 0.05$), indicating that GV was catching up with BA. Before and after the treatment, GV, HtSDSCA, and HtSDSBA between two groups were not significantly different ($P > 0.05$) [Table 3].

---

**Table 2: The sexual characters and the results of GnRH releasing test in ICPP girls before and after the leuprorelin therapy**

| Items                                | Before therapy | 3 months after the treatment | 6 months after the treatment |
|--------------------------------------|----------------|-----------------------------|-----------------------------|
|                                      | Test group     | Control group               | Test group                  | Control group               |
| Uterus volume (mean $\pm$ SD cm$^3$) | $3.40 \pm 2.90$ | $3.13 \pm 2.27$             | $2.21 \pm 2.10^*$          | $1.99 \pm 1.86^*$          |
|                                      | $3.39 \pm 2.90$ | $3.12 \pm 2.27$             | $2.20 \pm 2.10^*$          | $1.82 \pm 1.75^*$          |
| Left ovary volume (ml)               | $2.21 (1.03–6.77)$| $2.15 (1.04–4.76)$          | $1.29^* (0.16–5.37)$       | $0.90^* (0.10–2.89)$       |
|                                      | $2.19 (1.01–5.60)$| $2.13 (1.02–3.77)$          | $1.22^* (0.14–3.72)$       | $0.92^* (0.08–2.77)$       |
| Right ovary volume (ml)              | $1.96 (1.01–5.60)$| $1.93 (1.02–3.77)$          | $1.32^* (0.34–3.30)$       | $0.90^* (0.08–2.24)$       |
| Estradiol (mean $\pm$ SD, ×10$^6$ mg/L) | $37.10 \pm 14.70$| $36.00 \pm 17.30$           | $18.70 \pm 6.80^*$         | $13.50 \pm 5.30^*$         |
|                                      | $36.70 \pm 14.70$| $34.00 \pm 17.30$           | $16.00 \pm 6.80^*$         | $12.30 \pm 5.30^*$         |
| Peak value of LH (mean $\pm$ SD, U/L) | $16.60 \pm 7.50$| $16.40 \pm 6.60$            | $18.70 \pm 6.20^*$         | $1.85 \pm 0.67^*$          |

*$P < 0.05$, versus before treatment in the same group; †$P > 0.05$, comparison between two groups at the same time point, bilateral ovarian volume used nonparametric test (Wilcoxon test). SD: Standard deviation; ICPP: Idiopathic central precocious puberty; GnRH: Gonadotropin-releasing hormone; LH: Luteinizing hormone.

---

**Table 3: The height, weight, BA, GV, and PAH in ICPP girls before and after the leuprorelin therapy (mean $\pm$ SD)**

| Items       | Before treatment | 3 months after the treatment | 6 months after the treatment |
|-------------|------------------|-----------------------------|-----------------------------|
|             | Test group       | Control group               | Test group                  | Control group               |
| Height (cm) | $130 \pm 8$      | $129 \pm 5$                 | $132 \pm 8^*$               | $133 \pm 8^*$               |
| Weight (kg) | $27.5 \pm 5.40$  | $27.30 \pm 5.00$            | $28.10 \pm 5.40^*$          | $28.80 \pm 5.50^*$          |
| BA (years)  | $9.22 \pm 1.43$  | $9.11 \pm 1.18$             | $9.23 \pm 1.42^*$           | $9.24 \pm 1.36^*$           |
| GV (cm/year)| $7.43 \pm 1.36$  | $7.70 \pm 1.62$             | $6.28 \pm 1.42^*$           | $4.76 \pm 2.23^*$           |
| HtSDSCA     | $0.71 \pm 0.29$  | $0.69 \pm 0.32$             | $0.70 \pm 0.30^*$           | $0.69 \pm 0.29^*$           |
| HtSDSBA     | $0.47 \pm 0.48$  | $0.48 \pm 0.40$             | $0.24 \pm 0.55^*$           | $0.21 \pm 0.57^*$           |

*$P < 0.05$, vs. before treatment in the same group; †$P > 0.05$, comparison between two groups at the same time point. BA: Bone age; ICPP: Idiopathic central precocious puberty; SD: Standard deviation; PAH: Predicted adult height; GV: Growth velocity; HtSDSBA: Height standard deviation score for bone age; HtSDSCA: Height standard deviation score for chronology age.

---

Chinese Medical Journal | May 20, 2015 | Volume 128 | Issue 10
Safety
During the treatment, in the test group, 8 patients developed pain and swelling in the injection site, 5 patients appeared vaginal bleeding after the first dose of the drug; in the control group, 5 patients developed pain and swelling in the injection site, 2 patients appeared vaginal bleeding after the first dose of the drug. Swelling spontaneously alleviated about 2 weeks later without any therapeutic treatment in children of both groups, vaginal bleeding no longer appear during the subsequent course of the treatment. Thyroid, adrenal, electrolytes, bone metabolism, liver and renal function, blood lipids, glucose tolerance test, and glycosylated hemoglobin were detected before and after the treatment, and all of them were normal.

Discussion
With the improvement of living level and the impact of environmental factors, growth and development of children in our country are accelerated, the time of adolescence is advanced, in general. In recent years, the number of outpatient with precocious puberty was increasing. Precocious puberty has become the second place of pediatric endocrine disorders and the serious threat to children’s mental and physical health and physical development.\[15-17\]

Gonadotropin-releasing hormone analogue has been used in the treatment of CPP for more than 20 years. Its efficacy and safety have been accepted in the world. GnRHa has no significant adverse effect on growth, reproduction, and bone metabolism in future in children with precocious puberty.\[18-20\]
The age of menarche in girls with ICPP is near the normal age of menarche when the GnRHa treatment is stopped.\[12\]

During the treatment of GnRHa, some children may develop vaginal bleeding, the incidence of which was various in different clinical studies, was 5–9% or even 16–60%.\[21\] especially more common in those who had menarche. Vaginal bleeding usually occurred at 2 weeks after the first dose of the drug, occurred after the second dose in a few cases. This phenomenon is continued after 6 months in rare cases. Its duration is usually 3–5 days, even up to 11–13 days in a few patients.

The clinical study, a multi-center, randomized, parallel, positive control, prospective clinical trials, objectively evaluated the clinical effectiveness of the drug, obtained the clinical data of domestic leuprolide in the treatment of ICPP, and provided reference for the treatment of girls with ICPP. Furthermore, domestic drugs of efficacy equivalence, low-cost are very important for the relatively poor families and are also of certain significance for supporting national enterprises.

The percentage of children with an peak LH <3.3 U/L at 6 months of treatment in test and control groups were 96.80% and 96.20%, respectively, and the percentage of children with peak LH/FSH ratio <0.6 were 93.60% and 93.70%, respectively, there were no differences between the two groups, which were consistent with a foreign multi-center clinical study that the percentage of children with an peak LH <3.3 U/L at 6 months of treatment was 96.3%, and the percentage of children with peak LH/FSH ratio <0.6 was 94.4%.\[22\]

In this study, the mammary gland mass became softer and smaller, and the breast shrank after the treatment in test and control groups. In both groups, the development of secondary sexual characteristics such as breasts, pubic hair, and armpit hair were effectively inhibited; menstruation disappeared in children who have occurred menarche.

In the study, the uterus volume of patients in both groups before the treatment was significantly higher than the prepubertal level, and decreased to the prepubertal level after 6 months of treatment, the differences compared with pre-treatment in both groups were significant (all \( P < 0.05 \)). Bilateral ovaries volume before the treatment increased 1 ml significantly compared with the prepubertal level in patients of both groups. It was decreased to the prepubertal level at 6 months after treatment, the difference was significant (all \( P < 0.05 \)) compared with pre-treatment. Follicles with diameter \( \geq 4 \) mm disappeared after the treatment in all patients of both groups. Serum sex hormone level returned to the prepubertal level in children of both groups; the GV and the growth rate of BA were decreased.

The objective of the study was to evaluate the clinical efficacy and safety of domestic leuprolerin in girls with ICPP. The clinical indicators used in the study are the national and international accepted classic indicators for evaluating the degree of gonadal inhibition. The clinical observation period of the imported GnRHa was employed as the observation period of the study, which was 6 months. Therefore, this clinical study has some limitations. First, the duration of observation was short, only 6 months, the further data should be collected. The children should be followedup as long as possible up to their adulthood; second, the sample size was not large enough, the related safety data have been gradually expanded sample size, further analysis should be conducted; finally, there was no updated observation indicator in this clinical study. In future, updated indicators could be added in studies to research their scientific significances.

In conclusion, in the treatment of girls with ICPP, the efficacy and safety of domestic leuprolerin were comparable with imported leuprolerin. The results of this study were consistent with reported results\[22-25\] in literature, provided a reference for the clinical treatment of ICPP. Domestic leuprolerin may safely and effectively used in the treatment of ICPP, is worthy of clinical application and promotion.

Acknowledgments
The authors would like to thank Beijing Bozhiyin TandS Co., Ltd. and Clinical Drug Research Center of Shanghai University of Traditional Chinese Medicine, for conducting the data management and the statistical analysis of the study.

References
1. Soriano-Guillén L, Corripió R, Labarta JL, Cahuete R, Castro-Feijóo L, Espino R, et al. Czentral precocious puberty in children living in Spain:...
Incidence, prevalence, and influence of adoption and immigration. J Clin Endocrinol Metab 2010;95:4305-13.
2. Massart F, Seppia P, Pardi D, Lucchesi S, Messois C, Gagliardi L, et al. High incidence of central precocious puberty in a bounded geographic area of northwest Tuscany: An estrogen disruptor epidemic? Gynecol Endocrinol 2005;20:92-8.
3. Lin F, Zheng CH, Li H, Pan LL, Rao GF, Zeng AP, et al. Investigation and research about precocious puberty in eastern coast of Zhejiang Province. J Appl Clin Pediatr 2004;19:640-2.
4. Cai DP. Progress of precocious puberty in children. J Appl Clin Pediatr 2005;20:497-9.
5. Hu HY, Cheng H, Wang HL, Wang LH, Li JJ, Zhou XF, et al. Epidemiological analysis of sexual precocity of children aged 3-12 years old in Jiu jiang (in Chinese). Chin J Child Health Care 2012;20:985-7.
6. Wei HY, Chen YX, Li CZ, Wang LF, Luo SY, Zhang YH, et al. Study on prevalence of precocious puberty in children in Zhengzhou Region. J Appl Clin Pediatr 2010;25:1568-70.
7. Zhao L, Zhong Y. Effects of central precocious puberty on physical and sexual development in children (in Chinese). Chin J Contemp Pediatr 2014;16:555-9.
8. Tanaka T, Niimi H, Matsuo N, Fujieda K, Tachibana K, Ohyama K, et al. Results of long-term follow-up after treatment of central precocious puberty with leuprorelin acetate: Evaluation of effectiveness of treatment and recovery of gonadal function. The TAP-144-SR Japanese Study Group on Central Precocious Puberty. J Clin Endocrinol Metab 2005;90:1371-6.
9. Subspecialty Group of Endocrinology, Hereditary and Metabolic Diseases, Society of Pediatrics, Chinese Medical Association. Guidelines for diagnosis and treatment of central (true) precocious puberty (in Chinese). Chin J Pediatr 2007;45:426-7.
10. Ministry of Health of the People's Republic of China. Guideline on diagnosis and treatment of precocious puberty (pilot) (in Chinese). Chin J Child Health Care 2011;19:390-2.
11. Liu J, Tu JS. Progress of the clinical application and the drug delivery system of leuprolrelin acetate. Pharm Clin Res 2009;17:309-15.
12. Baek JW, Nam HK, Jin D, Oh YJ, Rhee YJ, Lee KH. Age of menarche and near adult height after long-term gonadotropin-releasing hormone agonist treatment in girls with central precocious puberty. Ann Pediatr Endocrinol Metab 2013;18:173-8.
13. Gillis D, Karavani G, Hirsch HJ, Strich D. Time to menarche and final height after histrelin implant treatment for central precocious puberty. J Pediatr 2013;163:532-6.
14. Li H, Ji CY, Zong XN, Zhang YQ. Height and weight standardized growth charts for Chinese children and adolescents aged 0 to 18 years (in Chinese). Chin J Pediatr 2009;47:487-92.
15. Yum T, Lee S, Kim Y. Association between precocious puberty and some endocrine disruptors in human plasma. J Environ Sci Health A Tox Hazard Subst Environ Eng 2013;48:912-7.
16. Poli F, Pizza F, Mignot E, Ferri R, Pagotto U, Taheri S, et al. High prevalence of precocious puberty and obesity in childhood narcolepsy with cataplexy. Sleep 2013;36:175-81.
17. Lee HS, Park HK, Ko JH, Kim YJ, Hwang JS. Utility of Basal luteinizing hormone levels for detecting central precocious puberty in girls. Horm Metab Res 2012;44:851-4.
18. Park HK, Lee HS, Ko JH, Hwang IT, Lim JS, Hwang JS. The effect of gonadotrophin-releasing hormone agonist treatment over 3 years on bone mineral density and body composition in girls with central precocious puberty. Clin Endocrinol (Oxf) 2012;77:743-8.
19. Pasquino AM, Pucarelli I, Accardo F, Demiraj V, Segni M, Di Nardo R. Long-term observation of 87 girls with idiopathic central precocious puberty treated with gonadotropin-releasing hormone analogs: Impact on adult height, body mass index, bone mineral content, and reproductive function. J Clin Endocrinol Metab 2008;93:190-5.
20. Inman M, Hursch BE, Mokashi A, Pinto T, Metzger DL, Cummings EA. Occurrence of slipped capital femoral epiphysis in children undergoing gonadotropin-releasing hormone agonist therapy for the treatment of central precocious puberty. Horm Res Paediatr 2013;80:64-8.
21. Seminara S, Nanni L, Generoso M, Mirri S, Leonardi V, Slabadzianiuik T, et al. Effect of treatment with cyproterone acetate on uterine bleeding at the beginning of GnRH analogue therapy in girls with idiopathic central precocious puberty. Horm Res Paediatr 2010;73:386-9.
22. Kim YJ, Lee HS, Lee YJ, Lim JS, Kim SY, Kim EY, et al. Multicenter clinical trial of leuprolide acetate depot (Luphere depot 3.75 mg) for efficacy and safety in girls with central precocious puberty. Ann Pediatr Endocrinol Metab 2013;18:173-8.
23. Kwon EB, Lee SJ, Cha M, Kim SY. Changes in the predicted adult height after gonadotropin-releasing hormone agonist treatment in girls with idiopathic true precocious puberty. Ann Pediatr Endocrinol Metab 2012;17:160-8.
24. Xie J, Wang WY, Yu J, Liu YQ, Xu B. Observation of the curative effect of domestic sustained release leuprolrelin acetate microspheres on children with central precocious puberty. China Trop Med 2013;13:872-4.
25. Xi L, Zhao ZH, Cheng RQ, Luo FH. Evaluation of the efficacy and safety of domestic gonadotropin-releasing hormone analogue in the treatment of girls with idiopathic central precocious puberty. Shanghai Med Pharm 2014;35:21-4.

Received: 01-12-2014 Edited by: Xin Chen

How to cite this article: Li WJ, Gong CX, Guo MJ, Xing J, Li T, Song WH, Luo XP, Wu D, Liang JP, Cao BY, Gu Y, Su C, Liang XJ, Liu M, Wang R, Li FT. Efficacy and Safety of Domestic Leuprolrelin in Girls with Idiopathic Central Precocious Puberty: A Multicenter, Randomized, Parallel, Controlled Trial. Chin Med J 2015;128:1314-20.

Source of Support: Nil. Conflict of Interest: None declared.